Expression of proliferating cell nuclear antigen in node-negative human prostate cancer

Anticancer Research

Volumn 16, Issue 5 A, 1996, Pages 2607-2611

  Idikio, Halliday A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Grade and stage; Prostate cancer PCNA

Indexed keywords

CYCLINE;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSURETHRAL RESECTION;

ANTIGENS, NEOPLASM; HUMANS; MALE; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0029966194     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Gronberg H, Bergh A, Damber JE, Jonsson H, Lenner P and Angstrom T: Prostate cancer in northern Sweden. Incidence, survival and mortality in relation to tumor grade. Acta Oncologia 33: 359-363, 1994.
2. Carter ES, Beatty TH, Steinberg GD, Childs B and Walsh PC: Mendelian inheritance of familial prostate cancer. PNAS 89: 3367-3371, 1992.
3. Gao X, Houn KV, Grignon D, Saker W and Chen YQ: Frequent loss of expression and loss of heterozygosity of the putative suppressor gene DCC in prostatic carcinoma. Cancer Res 53: 2723-2728, 1993.
4. Matsuyama H, Pan Y, Skoog L, Trihukait B, Naito K, Ekman P, Lichter P and Bergerheim US: Deletion mapping of chromosome 8p in prostate cancer by fluorescence insitu hybridization. Oncogene 9: 3071-3076, 1994.
5. Gao X, Wu N, Grignon D, Zacharek A, Liu H, Salkowski A, Li G, Sakr W, Sarkar F and Porter AT et al: High frequency of mutator phenotype in human prostate cancer. Oncogene 9: 2999-3003, 1994.
6. Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ and Pontes JE: Fluorescence in situ hybridization analyses of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 54: 3824-3830, 1994.
7. Gibbons RP: Localized Prostate Cancer: Surgical Management. Cancer 72: 2865-2872, 1994.
8. Paulson DF and Walther PJ: Is grade or stage of primary importance in determining the outcome after radical prostatectomy for disease clinically confined to the prostate? Br J Urol 63: 301-305, 1989.
9. Lange PH: Early detection of prostate cancer? J Natl Cancer Inst 83: 1199-1201, 1991.
10. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS and Epstein JI: Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease free survival among patients with prostate cancer. Cancer 70: 161-168, 1992.
11. Andriole GL: Serum prostate -specific antigen: The most useful tumor marker. J Clin Oncol 10: 1205-1207, 1992.
12. Benson MC and Olsson CA: Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management. Cancer 74: 1667-1673, 1994.
13. Chodak GW: Screening for Prostate Cancer. Europ J Urol 24: 3-5, 1993.
14. Bahnson RR: Treatment of Stage A1 Prostate Cancer: The Case for Treatment. Seminars in Urology 11: 54-57, 1993.
15. Montie JE: Observations on the epidemiology and natural history of prostate cancer. Urology 44: 2-8, 1994.
16. Hanawalt PC: Transcription-coupled repair and human disease. Science 266: 1957-1958, 1994.
17. Sancar A: Mechanisms of DNA excision repair. Science 266: 1954-1956, 1994.
18. Chodak GW: Early detection and screening for prostatic cancer. Urology 1989.
19. Vesalainen SLB, Lipponen PK, Talja MT, Alhava EM and Syrjänen KJ: Proliferation cell nuclear antigen and p53 expression as prognostic markers in T1-2 MO prostatic adenocarcinoma. Int J Cancer 58: 303-308, 1994.
20. Effert PJ, Neubauer A, Walther PJ and Liu ET: Alterations of the p53 gene are associated with the progression of a human prostate carcinoma. J Urol 147: 789-793, 1992.
21. Visakorpi T, Kalliomeni O-P, Heikkinen A, Koivula T and Isola J: Small subgroup of aggressive, highly proliferative prostate carcinomas def;ned by p53 accumulation. J National Cancer Inst 84: 883-887, 1992.
22. Kallakary BV, Figge J, Ross JS, Fisher HAG, Figge HL and Jennings TA: Association of p53 immunoreactivity with high Gleason tumor grade in prostate adenocarcinoma. Human Path 25: 92-97, 1994.
23. Gleason DF: Histologic grading of prostate cancer, A perspective. Human Pathol 23: 273-279, 1992.
24. Dohm G: Histopathology of prostate carcinoma. Diagnosis and differential diagnosis. Path Res Pract 179: 277-303, 1985.
25. Henke RP, Kruger E, Ayhan N, Hubner D, and Hammerer P: Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics. Virchows Archiv A 422: 61-66, 1993.
26. Van de Voorde WM, Elgamal AA, Van Poppel HP, Verbeken EK, Baert LV and Lauweryns JM: Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer 74: 3164-3175, 1994.
27. Willett CG, Warland G, Hagan MP, Daly WJ, Coen J, Shellito PC and Compton CC: Rectal cancer: the innuence of tumor proliferation on response to preoperative irradiation. Int J of Rad Oncol Biol Phys 32: 57-61, 1995.
28. Crook J, Robertson S and Esche B: Proliferative cell nuclear antigen in postradiotherapy prostate biopsies. Int J Rad Oncol Biol Physics 30: 303-308, 1994.
29. Tahan SR, Wei Y, Ling P and Bistrian BR: Influence of formalin fixation lime and tissue processing method on immunoreactivity of monoclonal antibody PC10 for proliferating cell nuclear antigen. Mod Path 8: 177-182, 1995.
30. Lundstrom M, Damber J-E and Bergh A: Prostatic tumor growth after initially successful castration therapy may be related to a decreased apoptotic cell death. Cancer Res 54: 4281-4284, 1994.